Company news

Wave Life Sciences Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023

April 25, 2023

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

April 19, 2023

Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days

March 28, 2023

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 21, 2023

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

March 1, 2023

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

February 8, 2023

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

December 18, 2022

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

December 12, 2022

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

November 8, 2022

Wave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022

November 2, 2022

Wave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses

October 2, 2022

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

September 27, 2022

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 26, 2022

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

September 19, 2022

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

September 15, 2022

Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

July 27, 2022

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

June 13, 2022

Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference

May 24, 2022

Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022

May 4, 2022

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

April 24, 2022

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 18, 2022

Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

April 3, 2022

Wave Life Sciences to Present at Stifel 2022 CNS Days

March 20, 2022

Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings

March 14, 2022

Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

March 6, 2022

Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 2, 2022

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

February 23, 2022

Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022

February 8, 2022

Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides

February 1, 2022

Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference

November 7, 2021

Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021

October 31, 2021

Wave Life Sciences and Takeda Amend CNS Collaboration

October 17, 2021

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy

September 28, 2021

Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast

September 27, 2021

Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference

September 21, 2021

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

September 8, 2021

Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021

September 7, 2021

Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences

September 6, 2021

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 4, 2021

Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021

July 25, 2021

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

July 19, 2021

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

June 1, 2021

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

May 27, 2021

Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

May 12, 2021

Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference

May 9, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 97 decks. Every deck is listed under its year.